Literature DB >> 17618868

t(11;19)(q21;p12~p13.11) and MECT1-MAML2 fusion transcript expression as a prognostic marker in infantile lung mucoepidermoid carcinoma.

Alexandre Serra1, Hans K Schackert, B Mohr, Anja Weise, Thomas Liehr, Guido Fitze.   

Abstract

BACKGROUND: Primary pulmonary mucoepidermoid carcinomas (MECs) are the third most frequent pulmonary malignant neoplasm in children, and new molecular diagnostics may prove useful in determining the biologic course of such tumors.
METHODS: We analyzed the presence of a balanced t(11;19)(q21; p12~p13.11) and the MECT1-MAML2 fusion transcript in a 9-year-old girl with mucoepidermoid lung carcinoma using conventional cytogenetics, fluorescence in-situ hybridization, spectral karyotyping, high-resolution multicolor banding, and reverse transcriptase-polymerase chain reaction.
RESULTS: We confirmed the t(11;19)(q21; p12~p13.11) in the tumor. Molecular analysis of the translocation breakpoint confirmed the presence of the MECT1-MAML2 fusion transcript postulated to lead to an altered cyclic adenosine monophosphate signaling in MEC.
CONCLUSIONS: Our data concur with previously reported cases, in which t(11;19) appears to be the primary chromosomal aberration for pulmonary MEC in children, and that the MECT1-MAML2 fusion transcript is associated with a better prognosis in MEC tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17618868     DOI: 10.1016/j.jpedsurg.2007.04.031

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  8 in total

Review 1.  Clinicopathologic and genetic features of primary bronchopulmonary mucoepidermoid carcinoma: the MD Anderson Cancer Center experience and comprehensive review of the literature.

Authors:  Alireza Salem; Diana Bell; Boris Sepesi; Vassiliki Papadimitrakopoulou; Adel El-Naggar; Cesar A Moran; Neda Kalhor
Journal:  Virchows Arch       Date:  2017-03-25       Impact factor: 4.064

2.  Role of LKB1-CRTC1 on glycosylated COX-2 and response to COX-2 inhibition in lung cancer.

Authors:  Chunxia Cao; Ruli Gao; Min Zhang; Antonio L Amelio; Mohammad Fallahi; Zirong Chen; Yumei Gu; Chengbin Hu; Eric A Welsh; Brienne E Engel; Eric B Haura; W Douglas Cress; Lizi Wu; Maria Zajac-Kaye; Frederic J Kaye
Journal:  J Natl Cancer Inst       Date:  2014-12-01       Impact factor: 13.506

3.  Epigenetic screening of salivary gland mucoepidermoid carcinoma identifies hypomethylation of CLIC3 as a common alteration.

Authors:  Zhiming Wang; Shizhang Ling; Eleni Rettig; Ryan Sobel; Marietta Tan; Elana J Fertig; Michael Considine; Adel K El-Naggar; Mariana Brait; Carole Fakhry; Patrick K Ha
Journal:  Oral Oncol       Date:  2015-10-17       Impact factor: 5.337

Review 4.  Childhood and adolescent tracheobronchial mucoepidermoid carcinoma (MEC): a case-series and review of the literature.

Authors:  Sergio Jaramillo; Yesenia Rojas; Bethany J Slater; Michael L Baker; M John Hicks; Jodi A Muscal; Timothy J Vece; David E Wesson; Jed G Nuchtern
Journal:  Pediatr Surg Int       Date:  2016-01-20       Impact factor: 1.827

5.  Treatment and survival outcomes based on histologic grading in patients with head and neck mucoepidermoid carcinoma.

Authors:  Melonie A Nance; Raja R Seethala; Yun Wang; Simion I Chiosea; Eugene N Myers; Jonas T Johnson; Stephen Y Lai
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

Review 6.  Landscape of gene fusions in epithelial cancers: seq and ye shall find.

Authors:  Chandan Kumar-Sinha; Shanker Kalyana-Sundaram; Arul M Chinnaiyan
Journal:  Genome Med       Date:  2015-12-18       Impact factor: 11.117

Review 7.  Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumors.

Authors:  Musaffe Tuna; Christopher I Amos; Gordon B Mills
Journal:  Oncotarget       Date:  2019-03-12

8.  Primary Pulmonary Mucoepidermoid Carcinoma: Histopathological and Moleculargenetic Studies of 26 Cases.

Authors:  Zhen Huo; Huanwen Wu; Ji Li; Shanqing Li; Shafei Wu; Yuanyuan Liu; Yufeng Luo; Jinling Cao; Xuan Zeng; Zhiyong Liang
Journal:  PLoS One       Date:  2015-11-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.